Table II shows that ZNF382 promoter methylation correlated with minimal residual disease (MRD; P=0.025). We found no significant differences in clinical characteristics, such as gender, age, FAB scores or cytogenetics between the patients with or without ZNF382 methylation (Table II). Kaplan-Meier survival analysis revealed similar survival times in the samples with ZNF382 promoter methylation (P=0.346) (Table III and Fig. 4A). Furthermore, multivariate analysis revealed that ZNF382 promoter methylation failed to be an independent prognostic factor in pediatric AML (P=0.249) (Table IV). Here, ZNF382 is linked to acute myeloid leukemia.